摘要
本综述考察了P2X受体的表达和在正常、病理心血管系统中的作用及其可能作为治疗靶点的潜力。 P2X受体是门控离子通道的配体,由内源性配体的ATP激活。它们由从七个中的( P2X1-7 )三个P2X亚基蛋白组成,可以结合形成同源或异源的P2X受体。该P2X1受体广泛表达于心血管系统,位于心脏和大多数血管和血小板的平滑肌中。有证据表明,高血压时交感神经的神经传递的嘌呤成分增加,确定了P2X1受体可作为这种疾病的可能的治疗靶点。P2X3和P2X2 / 3受体表达于心脏交感神经神经元,可能通过神经元ATP在这个预结合点的正反馈,放大交感神经的神经传递。表达于心脏的P2X受体的激活能增加心肌收缩力,这是P2X4受体已被确认的重要作用。P2X4受体在的缺失在心脏衰竭的模型中导致心脏收缩的抑制,而P2X4受体的过度表达已被证明是有心脏保护作用的,因此P2X4受体可能成为心脏病的治疗靶点。P2X受体已在内皮细胞上被鉴别出。虽然所有P2X1-7受体蛋白质的免疫反应已在内皮上表现出来,除了内皮P2X4受体已被证明介导了剪切应力过程中释放ATP的内皮依赖性血管舒张,我们对其功能的认识相对甚少。在此,我们对P2X受体作为心血管疾病的治疗中的治疗目标的潜力进行了讨论。
关键词: ATP,心血管疾病,心血管系统,血管内皮细胞, P2X受体,交感神经,血管平滑肌
Current Medicinal Chemistry
Title:P2X Receptors in the Cardiovascular System and their Potential as Therapeutic Targets in Disease
Volume: 22 Issue: 7
Author(s): Vera Ralevic
Affiliation:
关键词: ATP,心血管疾病,心血管系统,血管内皮细胞, P2X受体,交感神经,血管平滑肌
摘要: This review considers the expression and roles of P2X receptors in the cardiovascular system in health and disease and their potential as therapeutic targets. P2X receptors are ligand gated ion channels which are activated by the endogenous ligand ATP. They are formed from the assembly of three P2X subunit proteins from the complement of seven (P2X1-7), which can associate to form homomeric or heteromeric P2X receptors. The P2X1 receptor is widely expressed in the cardiovascular system, being located in the heart, in the smooth muscle of the majority of blood vessels and in platelets. P2X1 receptors expressed in blood vessels can be activated by ATP coreleased with noradrenaline as a sympathetic neurotransmitter, leading to smooth muscle depolarisation and contraction. There is evidence that the purinergic component of sympathetic neurotransmission is increased in hypertension, identifying P2X1 receptors as a possible therapeutic target in this disorder. P2X3 and P2X2/3 receptors are expressed on cardiac sympathetic neurones and may, through positive feedback of neuronal ATP at this prejunctional site, amplify sympathetic neurotransmission. Activation of P2X receptors expressed in the heart increases cardiac myocyte contractility, and an important role of the P2X4 receptor in this has been identified. Deletion of P2X4 receptors in the heart depresses contractile performance in models of heart failure, while overexpression of P2X4 receptors has been shown to be cardioprotective, thus P2X4 receptors may be therapeutic targets in the treatment of heart disease. P2X receptors have been identified on endothelial cells. Although immunoreactivity for all P2X1-7 receptor proteins has been shown on the endothelium, relatively little is known about their function, with the exception of the endothelial P2X4 receptor, which has been shown to mediate endothelium-dependent vasodilatation to ATP released during shear stress. The potential of P2X receptors as therapeutic targets in the treatment of cardiovascular disease is discussed.
Export Options
About this article
Cite this article as:
Vera Ralevic , P2X Receptors in the Cardiovascular System and their Potential as Therapeutic Targets in Disease, Current Medicinal Chemistry 2015; 22 (7) . https://dx.doi.org/10.2174/0929867321666141215094050
DOI https://dx.doi.org/10.2174/0929867321666141215094050 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aesthetic Cardiology: Adipose-Derived Stem Cells for Myocardial Repair
Current Stem Cell Research & Therapy Heart Failure in Sub-Saharan Africa
Current Cardiology Reviews Lipid-lowering Therapy in the Diabetic Foot: Seeing the Whole Iceberg and not Just the Tip
Current Vascular Pharmacology Novel Approaches in the Treatment of Antipsychotic-Induced Hyperprolactinemia: The Role of Partial Agonists of D2 Dopaminergic Receptors
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Antioxidants in Peripheral Arterial Disease
Current Drug Targets New Advances in the Field of Calcium Channel Antagonists: Cardiovascular Effects and Structure-Activity Relationships
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Pleiotropic Effects of Rimonabant: Clinical Implications
Current Pharmaceutical Design Statins and Metabolism of High Density Lipoprotein
Cardiovascular & Hematological Agents in Medicinal Chemistry Effects of Dietary Coconut Oil on Erucic Acid Rich Rapeseed Oil-induced Changes of Blood Serum Lipids in Rats
Current Nutrition & Food Science Gender Bias in Acute Coronary Syndromes
Current Vascular Pharmacology CNS Drug Delivery Systems: Novel Approaches
Recent Patents on Drug Delivery & Formulation microRNAs: Promising Biomarkers and Therapeutic Targets of Acute Myocardial Ischemia
Current Vascular Pharmacology Haptoglobin Polymorphism and Lacunar Stroke
Current Neurovascular Research Mechanisms of Drug Induced QT Interval Prolongation
Current Drug Safety Diabetes-Induced Alterations in Renal Medullary Microcirculation and Metabolism
Current Diabetes Reviews Heart Failure in East Asia
Current Cardiology Reviews Editorial [(Poly)phenol Chemistry: Part II - Physicochemical Properties & Biological Implications (Guest Editor: Stefan Chassaing)]
Current Organic Chemistry Anti-tumoral Properties of Endogenous Angiogenesis Inhibitors: A Case for Continued TIMP-2 Preclinical Development
Current Angiogenesis (Discontinued) Withdrawal Notice: Reconnoitering the Role of Endothelin in Obesity
Current Pharmaceutical Design Comparative Effect of Telmisartan vs Lisinopril on Blood Pressure in Patients of Metabolic Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets